mTOR — ìèøåíü ðàïàìèöèíà ó ìëåêîïèòàþùèõ (mammalian target of rapamycin)
NB! — âàæíî, îáðàòèòü âíèìàíèå (nota bene)
NICE — Íàöèîíàëüíûé èíñòèòóò çäîðîâüÿ è êëèíè÷åñêîãî ñîâåðøåíñòâîâàíèÿ (êà÷åñòâà ìåäèöèíñêîé ïîìîùè) Âåëèêîáðèòàíèè (National Institute for Health and Clinical Excellence)
NK — åñòåñòâåííûå êëåòêè-êèëëåðû (natural killer) NMDA — È-ìåòèë-Â-àñïàðòàò (N-methyl-D-aspartate)
NNT — ÷èñëî áîëüíûõ, êîòîðûõ íåîáõîäèìî ïðîëå÷èòü, ÷òîáû äîñòè÷ü êàêîãî-òî óêàçàííîãî ýôôåêòà (number need to treatment)
OR — îòíîøåíèå øàíñîâ (odds ratio)
paCO2 — ïàðöèàëüíîå äàâëåíèå óãëåêèñëîãî ãàçà â àðòåðèàëüíîé êðîâè
PALS — êóðñû ðàñøèðåííûõ ðåàíèìàöèîííûõ ìåðîïðèÿòèé â ïåäèàòðèè (Pediatric Advanced Life Support)
PANDAS — àóòîèììóííîå íåéðîïñèõèàòðè÷åñêîå ðàññòðîéñòâî â äåòñêîì âîçðàñòå, àññîöèèðîâàííîå ñî ñòðåïòîêîêêîâîé èíôåêöèåé (pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection)
 õîäå ïîäãîòîâêè ñòàòåé ïî ðåâìàòîëîãèè â òåðàïèè äëÿ ïîëüçîâàòåëåé ñàéòà ÌåäÓíèâåð èñïîëüçîâàíû òðóäû ñëåäóþùèõ àâòîðîâ:
Barturen G, Alarcon-Riquelme ME. SLE redefined on the basis of molecular pathways. Best Pract Res Clin Rheumatol. 2017; 31: 291–305.
Tavakolpour S. Towards personalized medicine for patients with autoimmune diseases: opportunities and challenges. Immunol Lett. 2017; 190: 130–138.
Orr C, Vireira-Sousa E, Boyle DL, et al. Synovial tissue research: a state-of-the-art review. Nat Rev Rheumatol. 2017; 13: 463–475.
Wu J, Li X, Song W, et al. The roles and applications of autoantibodies in progression, diagnosis, treatment and prognosis of human malignant tumours. Autoimmun Rev. 2017; 16: 1270–1281.
Yoest JM. Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review. Immunotargets Ther. 2017; 6: 73–82.
Kostine M, Rouxel L, Barnetche T, et al. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis. 2018; 77: 393–398.
Dejaco C, Brouwer E, Mason JC, et al. Giant cell arteritis and polymyalgia rheumatic: current challenges and opportunities. Nat Rev Rheumatol. 2017; 13: 578–592.
Ospelt C, Frank-Bertoncelj M. Why location matters—site-specific factors in rheumatic diseases. Nat Rev Rheumatol. 2017; 13: 433–442.
Suresh E. Laboratory tests in rheumatology: a rational approach. Cleve Clin J Med. 2019; 86: 198–210.
Fatemi G, Kermani TA. Clinical significance of a positive antinuclear antibody test. JAMA. 2015; 314: 827–828.
Grygiel-Gorniak B, Rogacka N, Puszczewicz M. Antinuclear antibodies in healthy people and non-rheumatic diseases—diagnostic and clinical implications. Reumatologia. 2018; 56: 243–248.
Bui VL, Kermani TA. Clinical significance of a positive antineutrophil cytoplasmic antibody (ANCA) test. JAMA. 2016; 316: 984–985.
George MD, Giles JT, Katz PP, et al. The impact of obesity and adiposity on inflammatory markers in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2017; 69: 1789–1798.
Derksen VF, Ajeganova S, Trouw LA, et al. Rheumatoid arthritis phenotype at presentation differs depending on the number of autoantibodies present. Ann Rheum Dis. 2017; 76: 716–720.
Miller A, Nightingale AL, Sammon CJ, et al. Estimating the diagnostic accuracy of rheumatoid factor in UK primary care: a study using the Clinical Practice Research Datalink. Rheumatology (Oxford). 2015; 54: 1882–1889.
Malmstrom V, Catrina Al, Klareskog L. The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting. Nat Rev Immunol. 2017; 17: 60–75.
van Zanten A, Arends S, Roozendaal C, et al. Presence of anticitrullinated protein antibodies in a large population-based cohort from the Netherlands. Ann Rheum Dis. 2017; 76: 1184–1190.
Heselden EL, Freemont AJ. Synovial fluid findings and demographic analysis of patients with coexistent intra-articular monosodium urate and calcium pyrophosphate crystals. J Clin Rheumatol. 2016; 22: 68–70.
Pisetsky DS. Antinuclear antibody testing: misunderstood or misbegotten? Nat Rev Rheumatol. 2017; 13: 495–502.
Stochmal A, Czuwara J, Trojanowska M, et aL Antinuclear antibodies in systemic sclerosis: an update. Clin Rev Allergy Immunol 2019. [Epub ahead of print.]
Fatemi G, Kermani ÒÀ. Clinical significance of a positive antinuclear antibody test JAMA. 2015; 314: 827–828.
Qu C, Zhang J, Zhang X, et al. Value of combined detection of anti-nuclear antibody, anti-double- stranded DNA antibody and ÑÇ, C4 complements in the clinical diagnosis of systemic lupus erythematosus. Exp IherMed. 2019; 17: 1390–1394.
Pisetsky DS, Rovin BH, Lipsky PE. New perspectives in rheumatology: biomarkers as entry criteria for clinical trials of new therapies for systemic lupus erythematosus: the example of antinuclear antibodies and anti-DNA. Arthritis Rheumatol. 2017; 69: 487–493.
Satoh M, Tanaka S, Ceribelli A, et al. A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy. Clin Rev Allergy Immunol. 2017; 52: 1–19.
Gupta A, Johnson DH, Nagalla S. Antiphospholipid antibodies. JAMA. 2017; 318: 959–960.
Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med. 2018; 378: 2010–2021.
Birmingham DJ, Hebert LA. The complement system in lupus nephritis. Semin Nephrol. 201S; 35: 444–454.
Romero-Sanchez C, Benavides-Solarte M, Galindo-Ibanez I, et al. Frequency of positive ANCA test in a population with clinical symptoms suggestive of autoimmune disease and the interference of ÀÍÀ in its interpretation. Rheumatol Clin. 2019. [Epub ahead of print]
Csemok E, Mahrhold J, Hellmich B. Anti-neutrophil cytoplasm antibodies (ANCA): recent methodological advances-lead to new consensus recommendations for ANCA detection. J bnunol Methods. 2018; 456: 1–6.
Bui VL, Kermani ÒÀ. Clinical significance of a positive antineutrophil cytoplasmic antibody (ANCA) test. JAMA. 2016; 316: 984–985.
Comec D, Comec-Le Gall E, Fervenza FC, Specks U. ANCA-associated vasculitis: clinical utility of using ANCA specificity to classify patients. Nat Rev Rheumatol. 2016; 12: 570–579.
Kolopp-Sarda MN, Miossec P. Cryoglobulins: an update on detection, mechanisms and clinical contribution. Autoimmun Rev. 2018; 17: 457–464.
Muchtar E, Magen H, Gertz MA. How I treat cryoglobulinemia. Blood. 2017; 129: 289–298.
Jamar F, Versari A, Galli F, et al. Molecular imaging of inflammatory arthritis and related disorders. Semin Nucl Med. 2018; 48: 277–290.
Barile A, Arrigoni F, Bruno F, et al. Computed tomography and MR imaging in rheumatoid arthritis. Radiol Clin North Am. 2017; 55: 997–1007.
Garner HW, Wessell DE. Current status of ultrasound and dual-energy computed tomography in the evaluation of gout. Rheumatol Int. 2018; 38: 1339–1344.
Moller I, Janta I, Backhaus M, et al. The 2017 EULAR standardised procedures for ultrasound imaging in rheumatology. Ann Rheum Dis. 2017; 76: 1974–1979.
Rubin DA. MRI and ultrasound of the hands and wrists in rheumatoid arthritis. I. Imaging findings. Skeletal Radiol. 2019. [Epub ahead of print.]
Hayashi D, Roemer FW, Jarraya M, et al. Imaging in osteoarthritis. Radiol Clin North Am 2017; 55: 1085–1102.
Sollini M, Berchiolli R, Kirienko M, et al. PET/MRI in infection and inflammation. Semin Nucl Med. 2018; 48: 225–241.
Groenink M, den Hartog AW, Franken R, et al. Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. Eur Heart J. 2013; 34: 3491–3500.
Lacro RV, Dietz HC, Sleeper LA, et al. Atenolol versus losartan in children and young adults with Marfan’s syndrome. N Engl J Med. 2014; 371: 2061–2071.
Milleron O, Arnoult F, Ropers J, et al. Marfan Sartan: a randomized, double-blind, placebo-controlled trial. Eur Heart J. 2015; 36: 2160–2166.
Teixido-Tura G, Forteza A, Rodr?guez-Palomares J, et al. Losartan versus atenolol for prevention of aortic dilation in patients with Marfan syndrome. J Am Coll Cardiol. 2018; 72: 1613–1618.
Ong KT, Perdu J, De Backer J, et al. Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective, randomized, open, blinded-endpoints trial. Lancet. 2010; 376: 1476–1484.
Bishop N, Adami S, Ahmed SF, et al. Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial. Lancet. 2013; 382: 1424–1432.
Dwan K, Phillipi CA, Steiner RD, et al. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev. 2014; 7: CD005088.
Peracha H, Sawamato K, Averill L, et al. Molecular genetics and metabolism, special edition: diagnosis and prognosis of mucopolysaccharidosis IVA. Mol Genet Metab. 2018; 125: 18–37.
James RA, Singh-Grewal D, Lee SJ, et al. Lysosomal storage disorders: a review of the musculoskeletal features. J Paediatr Child Health. 2016; 52: 262–271.
Dornelles AD, Artigalas O, da Silva AA, et al. Efficacy and safety of intravenous laronidase for mucopolysaccharidosis type I: a systematic review and meta-analysis. PLoS ONE. 2017; 12: 1–18.
Boelens JJ, van Hasselt PM. Neurodevelopmental outcome after hematopoietic cell transplantation in inborn errors of metabolism: current considerations and future perspectives. Neuropediatrics. 2016; 47: 285–292.
Motas S, Haurigot V Garcia M, et al. CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome). JCI Insight. 2016; 1: 1–19.
Sakai LY, Keene DR, Renard M, De Backer J. FBN1: the disease-causing gene for Marfan syndrome and other genetic disorders. Gene. 2016; 591: 279–291.
Pyeritz RE. Etiology and pathogenesis of the Marfan syndrome: current understanding. Ann Cardiothorac Surg. 2017; 6: 595–598.
Gaisl T, Bratton DJ, Kohler M. The impact of obstructive sleep apnoea on the aorta. Eur Respir J. 2015; 46: 532–544.
Albuquerque EV Scalco RC, Jorge AA. Management of endocrine disease: diagnostic and therapeutic approach to tall stature. Eur J Endocrinol. 2017; 176: R339–R353.
Esfandiari H, Ansari S, Mohammad-Rabei H, et al. Management strategies of ocular abnormalities in patients with Marfan syndrome: current perspective. J Ophthalmic Vis Res. 2019; 14: 71–77.
David TE, David CM, Manlhiot C, et al. Outcomes of aortic valve-sparing operations in Marfan syndrome. J Am Coll Cardiol. 2015; 66: 1445–1453.
Franken R, Groenink M, de Waard V et al. Genotype impacts survival in Marfan syndrome. Eur Heart J. 2016; 37: 3285–3290.
Sobey G. Ehlers-Danlos syndrome: how to diagnose and when to perform genetic tests. Arch Dis Child. 2015; 100: 57–61.
Henneton P, Albuisson J, Adham S, et al. Accuracy of clinical diagnostic criteria for patients with vascular Ehlers-Danlos syndrome in a tertiary referral centre. Circ Genom Precis Med. 2019.
Forlino A, Marini JC. Osteogenesis imperfecta. Lancet. 2016; 387: 1657–1671.
Palomo T, Viaca T, Lazaretti-Castro M. Osteogenesis imperfecta: diagnosis and treatment. Curr Opin Endocrinol Diabetes Obes. 2017; 24: 381–388.
Tsang SH, Sharma T. Inborn errors of metabolism: pseudoxanthoma elasticum Adv Exp Med Biol. 2018; 1085: 187–189.
Kranenburg G, Visseren FLJ, de Borst GJ, et al. Arterial stiffening and thickening in patients with pseudoxanthoma elasticum. Atherosclerosis. 2018; 270: 160–165.
Hosen MJ, Van Nieuwerburgh F, Steyaert W, et al. Efficiency of exome sequencing for the molecular diagnosis of pseudoxanthoma elasticum. J Invest Dermatol. 2015; 135: 992–998.
Ozen S, Demirkaya E, Erer B, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis. 2016; 75: 644–651.
Hashkes PJ, Spalding SJ, Giannini EH, et al. Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial. Ann Intern Med. 2012; 157: 533–541.
De Benedetti F, Gattorno M, Anton J, et al. Canakinumab for the treatment of autoinflammatory recurrent fever syndromes. N Engl J Med. 2018; 378: 1908–1919.
Georgin-Lavialle S, Fayand A, Rodrigues F, et al. Autoinflammatory diseases: state of the art. Presse Med. 2019; 48: e25–e48.
Hoffman HM, Broderick L. The role of the inflammasome in patients with autoinflammatory diseases. J Allergy Clin Immunol. 2016; 138: 3–14.
Manthiram K, Zhou Q, Aksentijevich I, et al. The monogenic autoinflammatory diseases define new pathways in human innate immunity and inflammation. Nat Immunol. 2017; 18: 832–842.
Park YH, Wood G, Kastner DL, et al. Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS. Nat Immunol. 2016; 17: 914–921.
Chung LK, Park YH, Zheng Y, et al. The Yersinia virulence factor YopM hijacks host kinases to inhibit type III effector-triggered activation of the pyrin inflammasome. Cell Host Microbe. 2016; 20: 296–306.
Masters SL, Lagou V, Jeru I, et al. Familial autoinflammation with neutrophilic dermatosis reveals a regulatory mechanism of pyrin activation. Sci Transl Med. 2016; 8: 1–10.
Moghaddas F, Llamas R, De Nardo D, et al. A novel pyrin-associated autoinflammation with neutrophilic dermatosis mutation further defines 14-3-3 binding of pyrin and distinction to familial Mediterranean fever. Ann Rheum Dis. 2017; 76: 2085–2094.
Federici S, Vanoni F, Ben-Chetrit E, et al. An international Delphi survey for the definition of new classification criteria for familial Mediterranean fever, mevalonate kinase deficiency, TNF receptor-associated periodic fever syndromes, and cryopyrin-associated periodic syndrome. J Rheumatol. 2019; 46: 429–436.
Govoni M, Bortoluzzi A, Rossi D, et al. How I treat patients with adult onset Still’s disease in clinical practice. Autoimmun Rev. 2017; 16: 1016–1023.
van der Meer JW, Simon A. The challenge of autoinflammatory syndromes: with an emphasis on hyper-IgD syndrome. Rheumatology (Oxford). 2016; 55: ii23–ii29.
Tanaka T, Yoshioka K, Nishikomori R, et al. National survey of Japanese patients with mevalonate kinase deficiency reveals distinctive genetic and clinical characteristics. Mod Rheumatol. 2018; 1–7.
Borghini S, Ferrera D, Prigione I, et al. Gene expression profile in TNF receptor-associated periodic syndrome reveals constitutively enhanced pathways and new players in the underlying inflammation. Clin Exp Rheumatol. 2016; 34: S121–S128.
Rigante D, Frediani B, Cantarini L. A comprehensive overview of the hereditary periodic fever syndromes. Clin Rev Allergy Immunol. 2018; 54: 446–453.
ter Haar NM, Oswald M, Jeyaratnam J, et al. Recommendations for the management of autoinflammatory diseases. Ann Rheum Dis. 2015; 74: 1636–1644.
Zhong FL, Mamai O, Sborgi L, et al. Germline NLRP1 mutations cause skin inflammatory and cancer susceptibility syndromes via inflammasome activation. Cell. 2016; 167: 187–202.
Crow YJ, Manel N. Aicardi-Goutieres syndrome and the type I interferonopathies. Nat Rev Immunol. 2015; 15: 429–440.
Honda-Ozaki F, Terashima M, Niwa A, et al. Pluripotent stem cell model of Nakajo-Nishimura syndrome untangles proinflammatory pathways mediated by oxidative stress. Stem Cell Reports. 2018; 10: 1835–1850.
Brehm A, Liu Y, Sheikh A, et al. Additive loss-of-function proteasome subunit mutations in CANDLE/ PRAAS patients promote type I IFN production. J Clin Invest. 2015; 125: 4196–4211.
Zhou Q, Wang H, Schwartz DM, et al. Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease. Nat Genet. 2016; 48: 67–73.
Sikora KA., Bennett JR, Vyncke L, et al. Germline gain-of-function myeloid differentiation primary response gene-88 (MYD88) mutation in a child with severe arthritis. J Allergy Clin Immunol. 2018; 141: 1943–1947.
Moens L, Hershfield M, Arts K, et al. Human adenosine deaminase 2 deficiency: a multi-faceted inborn error of immunity. Immunol Rev. 2019; 287: 62–72.
Ombrello AK, Qin J, Hoffman PM, et al. Treatment strategies for deficiency of adenosine deaminase 2. N Engl J Med. 2019; 380: 1582–1584.
de Koning HD, van Gijn ME, Stoffels M, et al. Myeloid lineage-restricted somatic mosaicism of NLRP3 mutations in patients with variant Schnitzler syndrome. J Allergy Clin Immunol. 2015; 135: 561–564.
Gregori D, Giacovelli G, Minto C, et al. Association of pharmacological treatments with long-term pain control in patients with knee osteoarthritis: a systematic review and meta-analysis. JAMA. 2018; 320: 2564–2579.
Krebs EE, Gravely A, Nugent S, et al. Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain: the SPACE randomized clinical trial. JAMA. 2018; 319: 872–882.
Solomon DH, Husni ME, Wolski KE, et al. Differences in safety of nonsteroidal antiinflammatory drugs in patients with osteoarthritis and patients with rheumatoid arthritis: a randomized clinical trial. Arthritis Rheumatol. 2018; 70: 537–546.
McAlindon TE, LaValley MP, Harvey WF, et al. Effect of intra-articular triamcinolone vs saline on knee cartilage volume and pain in patients with knee osteoarthritis: a randomized clinical trial. JAMA. 2017; 317: 1967–1975.
Conaghan PG, Hunter DJ, Cohen SB, et al. Effects of a single intra-articular injection of a microsphere formulation of triamcinolone acetonide on knee osteoarthritis pain: a double-blinded, randomized, placebo-controlled, multinational study. J Bone Joint Surg Am. 2018; 100: 666–677.
Kingsbury SR, Tharmanathan P, Keding A, et al. Hydroxychloroquine effectiveness in reducing symptoms of hand osteoarthritis: a randomized trial. Ann Intern Med. 2018; 168: 385–395.
Skou ST, Roos EM, Laursen MB, et al. A randomized, controlled trial of total knee replacement. N Engl J Med. 2015; 373: 1597–1606.
Brignardello-Petersen R, Guyatt GH, Buchbinder R, et al. Knee arthroscopy versus conservative management in patients with degenerative knee disease: a systematic review. BMJ Open. 2017; 7: 1–12.
Roman-Blas JA, Bizzi E, Largo R, et al. An update on the up and coming therapies to treat osteoarthritis, a multifaceted disease. Expert Opin Pharmacother. 2016; 17: 1745–1756.
Lindner C, Thiagarajah S, Wilkinson JM, et al. Investigation of association between hip osteoarthritis susceptibility loci and radiographic proximal femur shape. Arthritis Rheumatol. 2015; 67: 2076–2084.
Kraus VB, Blanco FJ, Englund M, et al. Call for standardized definitions of osteoarthritis and risk stratification for clinical trials and clinical use. Osteoarthritis Cartilage. 2015; 23: 1233–1241.
Cisternas MG, Murphy L, Sacks JJ, et al. Alternative methods for defining osteoarthritis and the impact on estimating prevalence in a US population-based survey. Arthritis Care Res (Hoboken). 2016; 68: 574–580.
Jafarzadeh SR, Felson DT. Updated estimates suggest a much higher prevalence of arthritis in United States adults than previous ones. Arthritis Rheumatol. 2018; 70: 185–192.
Bricca A, Juhl CB, Grodzinsky AJ, et al. Impact of a daily exercise dose on knee joint cartilage—a systematic review and meta-analysis of randomized controlled trials in healthy animals. Osteoarthritis Cartilage. 2017; 25: 1223–1237.
Cibrian Uhalte E, Wilkinson JM, Southam L, et al. Pathways to understanding the genomic aetiology of osteoarthritis. Hum Mol Genet. 2017; 26: R193–R201.
Tachmazidou I, Hatzikotoulas K, Southam L, et al. Identification of new therapeutic targets for osteoarthritis through genome-wide analyses of UK Biobank data. Nat Genet. 2019; 51: 230–236.
Loughlin J. Genetic contribution to osteoarthritis development: current state of evidence. Curr Opin Rheumatol. 2015; 27: 284–288.
Niu J, Clancy M, Aliabadi P, et al. Metabolic syndrome, its components, and knee osteoarthritis: the Framingham osteoarthritis study. Arthritis Rheumatol. 2017; 69: 1194–1203.
Azamar-Llamas D, Hernandez-Molina G, Ramos-Avalos B, et al. Adipokine contribution to the pathogenesis of osteoarthritis. Mediators Inflamm. 2017; 2017: 1–26.
McCulloch K, Litherland GJ, Rai TS. Cellular senescence in osteoarthritis pathology. Aging Cell. 2017; 16: 210–218.
Hsueh M-F, Onnerfjord P, Bolognesi M, et al. Differential cartilage turnover along the human lower limb revealed by protein deamidation. Osteoarthritis Cartilage. 2018; 26 (suppl 1): S32–S32.
Watt FE, Paterson E, Freidin A, et al. Acute molecular changes in synovial fluid following human knee injury: association with early clinical outcomes. Arthritis Rheumatol. 2016; 68: 2129–2140.
Kraus VB, Collins JE, Hargrove D, et al. Predictive validity of biochemical biomarkers in knee osteoarthritis: data from the FNIH OA Biomarkers Consortium. Ann Rheum Dis. 2017; 76: 186–195.
Amano K, Huebner JL, Stabler TV et al. Synovial fluid profile at the time of anterior cruciate ligament reconstruction and its association with cartilage matrix composition 3 years after surgery. Am J Sports Med. 2018; 46: 890–899.
Lattermann C, Conley CE, Johnson DL, et al. Select biomarkers on the day of anterior cruciate ligament reconstruction predict poor patient-reported outcomes at 2-year follow-up: a pilot study. Biomed Res Int. 2018; 2018: 1–9.
McCabe PS, Parkes MJ, Maricar N, et al. Brief report: synovial fluid white blood cell count in knee osteoarthritis: association with structural findings and treatment response. Arthritis Rheumatol. 2017; 69: 103–107.
Roemer FW, Kwoh CK, Hayashi D, et al. The role of radiography and MRI for eligibility assessment in DMOAD trials of knee OA. Nat Rev Rheumatol. 2018; 14: 372–380.
Hayashi D, Roemer FW, Guermazi A. Imaging of osteoarthritis: recent research developments and future perspective. Br J Radiol. 2019; 14: 17–29.
Kogan F, Fan AP, Monu U, et al. Quantitative imaging of bone-cartilage interactions in ACL-injured patients with PET-MRI. Osteoarthritis Cartilage. 2018; 26: 790–796.
Kraus VB, McDaniel G, Huebner JL, et al. Direct in vivo evidence of activated macrophages in human osteoarthritis. Osteoarthritis Cartilage. 2016; 24: 1613–1621.
Wang X, Oo WM, Linklater JM. What is the role of imaging in the clinical diagnosis of osteoarthritis and disease management? Rheumatology (Oxford). 2018; 57: iv51–iv60.
Mathiessen A, Conaghan PG. Synovitis in osteoarthritis: current understanding with therapeutic implications. Arthritis Res Ther. 2017; 19: 1–4.
Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. Lancet. 2019; 393: 1745–1759.
Kloppenburg M, Kroon FP, Blanco FJ, et al. 2018 update of the EULAR recommendations for the management of hand osteoarthritis. Ann Rheum Dis. 2019; 78: 16–24.
Price AJ, Alvand A, Troelsen A, et al. Knee replacement. Lancet. 2018; 392: 1672–1682.
Ferguson RJ, Palmer AJ, Taylor A, et al. Hip replacement. Lancet. 2018; 392: 1662–1671.
Jones IA, Togashi R, Wilson ML, et al. Intra-articular treatment options for knee osteoarthritis. Nat Rev Rheumatol. 2019; 15: 77–90.
Jeon OH, Kim C, Laberge RM, et al. Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment. Nat Med. 2017; 23: 775–781.
Coombes BK, Bisset L, Vicenzino B. Efficacy and safety of corticosteroid injections and other injections for management of tendinopathy: a systematic review of randomised controlled trials. Lancet. 2010; 376: 1751–1767.
Rhon DI, Boyles RB, Cleland JA. One-year outcome of subacromial corticosteroid injection compared with manual physical therapy for the management of the unilateral shoulder impingement syndrome: a pragmatic randomized trial. Ann Intern Med. 2014; 161: 161–169.
Wu YC, Tsai WC, Tu YK, et al. Comparative effectiveness of nonoperative treatments for chronic calcific tendinitis of the shoulder: a systematic review and network meta-analysis of randomized controlled trials. Arch Phys Med Rehabil 2017; 98: 1678–1692.
Bannuru RR, Flavin NE, Vaysbrot E, et al. High-energy extracorporeal shock-wave therapy for treating chronic calcific tendinitis of the shoulder: a systematic review. Ann Intern Med. 2014; 160: 542–549.
Katz JN, Brophy RH, Chaisson CE, et al. Surgery versus physical therapy for a meniscal tear and osteoarthritis. N Engl J Med. 2013; 368: 1675–1684.
Sihvonen R, Paavola M, Malmivaara A, et al. Arthroscopic partial meniscectomy versus sham surgery for a degenerative meniscal tear. N Engl J Med. 2013; 369: 2515–2524.
Kise NJ, Risberg MA, Stensrud S, et al. Exercise therapy versus arthroscopic partial meniscectomy for degenerative meniscal tear in middle aged patients: randomised controlled trial with two year follow-up. BMJ. 2016; 354: i3740.
Sihvonen R, Englund M, Turkiewicz A, et al. Mechanical symptoms and arthroscopic partial meniscectomy in patients with degenerative meniscus tear: a secondary analysis of a randomized trial. Ann Intern Med. 2016; 164: 449–455.
Kim SH, Ha CW, Park YB, et al. Intra-articular injection of mesenchymal stem cells for clinical outcomes and cartilage repair in osteoarthritis ofthe knee: a meta-analysis of randomized controlled trials. Arch Orthop Trauma Surg. 2019; 139: 971–980.
Moraes VY, Lenza M, Tamaoki MJ, et al. Platelet-rich therapies for musculoskeletal soft tissue injuries. Cochrane Database Syst Rev. 2014; 4: CD010071.
Villasenor-Ovies P, Navarro-Zarra JE, Saavedra MA, et al. A survey of anatomical items relevant to the practice of rheumatology: upper extremity, head, neck spine, and general concepts. Clin Rheumatol 2016; 35: 3025–3030.
Bolon B. Mini-review: toxic tendinopathy. Toxicol Pathol. 2017; 45: 834–837.
Sconfienza LM, Alabano D, Allen G, et al. Clinical indications for musculoskeletal ultrasound updated in 2017 by European Society of Musculoskeletal Radiology (ESSR) consensus. Eur Radiol. 2018; 28: 5338–5351.
Allen GM. The diagnosis and management of shoulder pain. J Ultrason. 2018; 18: 234–239.
Huegel J, Williams AA, Soslowsky LJ. Rotator cuff biology and biomechanics: a review of normal and pathological conditions. Curr Rheumatol Rep. 2015; 17: 1–9.
Whittle S, Buchbinder R. In the clinic. Rotator cuff disease. Ann Intern Med. 2015; 162: ITC1–ITC15.
Shillito M, Soong M, Martin N. Radiographic and clinical analysis of lateral epicondylitis. J Hand Surg Am. 2017; 42: 436–442.
Kani K, Porrino J, Dahiya N, et al. Visualization of the soft tissues at the lateral and medial epicondyles of the elbow. PMR. 2017; 533–539.
Zibis AH, Mitrousias VD, Klontzas ME, et al. Great trochanter bursitis vs sciatica, a diagnostic- anatomic trap: differential diagnosis and brief review of the literature. Eur Spine J. 2018; 27: 1509–1516.
Shah A, James SL, Davies AM, et al. A diagnostic approach to popliteal fossa masses. Clin Radiol. 2017; 72: 323–337.
van der Vlist AC, Breda SJ, Oei EHG, et al. Clinical risk factors for Achilles tendinopathy: a systematic review. Br J Sports Med. 2019. [Epub ahead of print.]
Le ADK, Enweze L, DeBaun MR, et al. Platelet-rich plasma. Clin Sports Med. 2019; 38: 17–44.
Lamb SE, Williamson EM, Heine PJ, et al. Exercises to improve function of the rheumatoid hand (SARAH): a randomised controlled trial. Lancet. 2015; 385: 421–429.
Nam JL, Takase-Minegishi K, Ramiro S, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2017; 76: 1113–1136.
Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med. 2016; 375: 2519–2529.
Lopez-Olivo MA, Siddhanamatha HR, Shea B, et al. Methotrexate for treating rheumatoid arthritis. Cochrane Database Syst Rev. 2014; 6: CD000957.
Moreland LW, O’Dell JR, Paulus HE, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum. 2012; 64: 2824–2835.
Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014; 370: 2377–2386.
Genovese MC, Kremer JM, Kartman CE, et al. Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis. Rheumatology (Oxford). 2018; 57: 900–908.
Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017; 376: 652–662.
Genovese MC, Fleischmann R, Combe B, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet. 2018; 391: 2513–2524.
Burmester GR, Kremer JM, Van den Bosch F, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEX, 236T): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018; 391: 2503–2512.
Porter D, van Melckebeke J, Dale J, et al. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. Lancet. 2016; 388: 239–247.
Nam JL, Ramiro S, Gaujoux-Viala C, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2014; 73: 516–528.
Aletaha D, Bingham CO 3rd, Tanaka Y, et al. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study. Lancet. 2017; 389: 1206–1217.
Genovese MC, Kremer J, Zamani O, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016; 374: 1243–1252.
O’Dell JR, Curtis JR, Mikuls TR, et al. Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial. Arthritis Rheum. 2013; 65: 1985–1994.
O’Dell JR, Mikuls TR, Taylor TH, et al. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med. 2013; 369: 307–318.
Scott DL, Ibrahim F, Farewell V et al. Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial. BMJ. 2015; 350: 1–9.
Gottenberg JE, Brocq O, Perdriger A, et al. Non-TNF-targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug: a randomized clinical trial. JAMA. 2016; 316: 1172–1180.
Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018; 4: 1–23.
England BR, Thiele GM, Anderson DR, et al. Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. BMJ. 2018; 361: 1–17.
Yarwood A, Huizinga TW, Worthington J. The genetics of rheumatoid arthritis: risk and protection in different stages of the evolution of RA. Rheumatology (Oxford). 2016; 55: 199–209.
Guo Q, Wang Y, Xu D, et al. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018; 6: 1–14.
Makol A, Matteson EL, Warrington KJ. Rheumatoid vasculitis: an update. Curr Opin Rheumatol. 2015; 27: 63–70.
Nordberg LB, Lillegraven S, Aga AB, et al. Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial. RMD Open. 2018; 4: 11–17.
Schett G. The role of ACPAs in at-risk individuals: early targeting of the bone and joints. Best Pract Res Clin Rheumatol. 2017; 31: 53–58.
Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA. 2018; 320: 1360–1372.
Chatzidionysiou K, Emamikia S, Nam J, et al. Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2017; 76: 1102–1107.
Sparks JA. Rheumatoid arthritis. Ann Intern Med. 2019; 170: ITC1–ITC16.
Martin-Lopez M, Carmona L, Balsa A, et al. Serum drug levels of biologic agents in the management of rheumatoid arthritis and spondyloarthritis: a systematic review. Rheumatol Int. 2018; 38: 975–983.
Rutherford AI, Subesinghe S, Hyrich KL, et al. Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis. 2018; 77: 905–910.
Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management ofrheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017; 76: 960–977.
Lacaille D, Avina-Zubieta JA, Sayre EC, et al. Improvement in 5-year mortality in incident rheumatoid arthritis compared with the general population-closing the mortality gap. Ann Rheum Dis. 2017; 76: 1057–1063.
Viatte S, Plant D, Han B, et al. Association of HLA-DRB1 haplotypes with rheumatoid arthritis severity, mortality, and treatment response. JAMA. 2015; 313: 1645–1656.
Kroon FP, van der Burg LR, Ramiro S, et al. Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis). Cochrane Database Syst Rev. 2015; 7: CD010952.
Maxwell LJ, Zochling J, Boonen A, et al. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015; 4: CD005468.
Landew R, Sieper J, Mease P, et al. Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study. Lancet. 2018; 392: 134–144.
Song IH, Hermann KG, Haibel H, et al. Consistently good clinical response in patients with early axial spondyloarthritis after 3 years of continuous treatment with etanercept: longterm data of the ESTHER trial. J Rheumatol. 2014; 41: 2034–2040.
Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015; 373: 2534–2548.
van der Heijde D, Cheng-Chung Wei J, Dougados M, et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. 2018; 392: 2441–2451.
van der Heijde D, Baraliakos X, Gensler LS, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. Lancet. 2018; 392: 2378–2387.
Braun J, van der Horst-Bruinsma IE, Huang F, et al. Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum. 2011; 63: 1543–1551.
Barber CE, Kim J, Inman RD, et al. Antibiotics for treatment of reactive arthritis: a systematic review and metaanalysis. J Rheumatol. 2013; 40: 916–928.
Carter JD, Espinoza LR, Inman RD, et al. Combination antibiotics as a treatment for chronic Chlamydia-induced reactive arthritis: a double-blind, placebo-controlled, prospective trial. Arthritis Rheum. 2010; 62: 1298–1307.
Coates LC, Moverley AR, McParland L, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet. 2015; 386: 2489–2498.
Kavanaugh A, van der Heijde D, McInnes IB, et al. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum. 2012; 64: 2504–2517.
Deodhar A, Gottlieb AB, Boehncke WH, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2018; 391: 2213–2224.
Mease PJ, Genovese MC, Greenwald MW, et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med. 2014; 370: 2295–2306.
Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015; 373: 1329–1339.
Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017; 377: 1525–1536.
Mease P, Coates LC, Helliwell PS, et al. Efficacy and safety of filgotinib, a selective janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebocontrolled, phase 2 trial. Lancet. 2018; 392: 2367–2377.
Brown MA, Wordsworth BP. Genetics in ankylosing spondylitis—current state of the art and translation into clinical outcomes. Best Pract Res Clin Rheumatol. 2017; 31: 763–776.
Taurog JD, Chhabra A, Colbert RA.. Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med. 2016; 374: 2563–2574.
Khmelinskii N, Regel A, Baraliakos X. The role of imaging in diagnosing axial spondyloarthritis. Front Med (Lausanne). 2018; 5: 1–11.
Duba AS, Mathew SD. The seronegative spondyloarthropathies. Prim Care. 2018; 45: 271–287.
Dashti N, Mahmoudi M, Aslani S, et al. HLA-B*27 subtypes and their implications in the pathogenesis of ankylosing spondylitis. Gene. 2018; 670: 15–21.
Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019; 80: 251–265.
Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018; 391: 2273–2284.
Mease P, Strand V, Gladman D. Functional impairment measurement in psoriatic arthritis: importance and challenges. Semin Arthritis Rheum. 2018; 48: 436–448.
Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016; 75: 499–510.
Zao A, Cantista P. The role ofland and aquatic exercise in ankylosing spondylitis: a systematic review. Rheumatol Int. 2017; 37: 1979–1990.
Van den Bosch F, Coates L. Clinical management of psoriatic arthritis. Lancet. 2018; 391: 2285–2294.
Gupta N, Agarwal A. Management of uveitis in spondyloarthropathy: current trends. Perm J. 2018; 22: 1–19.
Ward MM, Deodhar A, Akl EA, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2016; 68: 282–298.
Singh JA, Guyatt G, Ogdie A, et al. Special Article: 2018 American College of Rheumatology/ National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 2016; 68: 282–298.
Peluso R, Manguso F, Vitiello M, et al. Management of arthropathy in inflammatory bowel diseases. Ther Adv Chronic Dis. 2015; 6: 65–77.
Conigliaro P, Chimenti MS, Ascolani M, et al. Impact of a multidisciplinary approach in enteropathic spondyloarthritis patients. Autoimmun Rev. 2016; 15: 184–190.
Rojas-Villarraga A, Torres-Gonzalez JV, Ruiz-Stemberg AM. Safety ofhormonal replacement therapy and oral contraceptives in systemic lupus erythematosus: a systematic review and meta-analysis. PLoS ONE. 2014; 9: 1–11.
Houssiau FA, Vasconcelos C, D’Crus D, et al. The 10-year follow-up data ofthe Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis. 2010; 69: 61–64.
Houssiau FA, D’Cruz D, Sangle S, et al. MAINTAIN Nephritis Trial Group. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis. 2010; 69: 2083–2089.
Liu Z, Zhang H, Liu Z, et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med. 2015; 162: 18–26.
Ordi-Ros J, Saez-Comet L, Perez-Conesa M, et al. Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial. Ann Rheum Dis. 2017; 76: 1575–1582.
Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011; 377: 721–731.
Furie R, Khamashta M, Merrill JT, et al. Anifrolumab, an anti-interferon-a receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol. 2017; 69: 376–386.
Palmer SC, Tunnicliffe DJ, Singh-Grewal D, et al. Induction and maintenance immunosuppression treatment of proliferative lupus nephritis: a network meta-analysis of randomized trials. Am J Kidney Dis. 2017; 70: 324–336.
Rathi M, Goyal A, Jaryal A, et al. Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis. Kidney Int. 2016; 89: 235–242.
Dooley MA, Jayne D, Ginzler EM, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011; 365: 1886–1895.
Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011; 63: 3918–3930.
Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis. Arthritis Rheum. 2012; 64: 1215–1226.
Dall’Era M, Cisternas MG, Snipes K, et al. The incidence and prevalence of systemic lupus erythematosus in San Francisco County, California: the California Lupus Surveillance Project. Arthritis Rheumatol. 2017; 69: 1996–2005.
Izmirly PM, Wan I, Sahl S, et al. The incidence and prevalence of systemic lupus erythematosus in New York County (Manhattan), New York: the Manhattan Lupus Surveillance Program. Arthritis Rheumatol. 2017; 69: 2006–2017.
Stojan G, Petri M. Epidemiology of systemic lupus erythematosus: an update. Curr Opin Rheumatol. 2018; 30: 144–150.
Ugarte-Gil MF, Pons-Estel GJ, Molineros J, et al. Disease features and outcomes in United States lupus patients of Hispanic origin and their Mestizo counterparts in Latin America: a commentary. Rheumatology (Oxford). 2016; 55: 436–440.
Langefeld CD, Ainsworth HC, Cunninghame Graham DS, et al. Transancestral mapping and genetic load in systemic lupus erythematosus. Nat Commun. 2017; 8: 1–18.
Hajishengallis G, Lambris JD. More than complementing Tolls: complement-Toll-like receptor synergy and crosstalk in innate immunity and inflammation. Immunol Rev. 2016; 274: 233–244.
Crow MK, Olferiev M, Kirou KA. Type I interferons in autoimmune disease. Annu Rev Pathol. 2019; 14: 369–393.
Alarcon-Riquelme ME. New attempts to define and clarify lupus. Curr Rheumatol Rep. 2019; 21: 1–7.
Leffers HCB, Lange T, Collins C, et al. The study of interactions between genome and exposome in the development of systemic lupus erythematosus. Autoimmun Rev. 2019. [Epub ahead of print.]
Kim H, Sanchez GA, Goldbach-Mansky R. Insights from Mendelian interferonopathies: comparison of CANDLE, SAVI with AGS, monogenic lupus. J Mol Med. 2016; 94: 1111–1127.
Crowl JT, Gray EE, Pestal K, et al. Intracellular nucleic acid detection in autoimmunity. Annu Rev Immunol. 2017; 35: 313–336.
Barbhaiya M, Costenbader KH. Environmental exposures and the development of systemic lupus erythematosus. Curr Opin Rheumatol. 2016; 28: 497–505.
Greiling TM, Dehner C, Chen X, et al. Commensal orthologs of the human autoantigen Ro60 as triggers of autoimmunity in lupus. Sci Transl Med. 2018; 10: 1–15.
Kaul A, Gordon C, Crow MK, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016; 2: 1–21.
Mohan S, Barsalou J, Bradley TJ, et al. Endothelial progenitor cell phenotype and function are impaired in childhood-onset systemic lupus erythematosus. Arthritis Rheumatol. 2015; 67: 2257–2262.
Bialas AR, Presumey J, Das A, et al. Microglia-dependent synapse loss in type I interferon-mediated lupus. Nature. 2017; 546: 539–543.
Clark MR, Trotter K, Chang A. The pathogenesis and therapeutic implications of tubulointerstitial inflammation in human lupus nephritis. Semin Nephrol. 2015; 35: 455–464.
Bajema IM, Wilhelmus S, Alpers CE, et al. Revision of the International Society of Nephrology/ Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 2018; 93: 789–796.
Lewandowski LB, Kaplan MJ. Update on cardiovascular disease in lupus. Curr Opin Rheumatol. 2016; 28: 468–476.
Hanly JG, Kozora E, Beyea SD, et al. Review: nervous system disease in systemic lupus erythematosus: current status and future directions. Arthritis Rheumatol. 2019; 71: 33–42.
Arkema EV Palmsten K, Sjowall C, et al. What to expect when expecting with systemic lupus ery¬thematosus (SLE): a population-based study of maternal and fetal outcomes in SLE and pre-SLE. Arthritis Care Res (Hoboken). 2016; 68: 988–994.
Izmirly P, Saxena A, Buyon JP. Progress in the pathogenesis and treatment of cardiac manifestations of neonatal lupus. Curr Opin Rheumatol. 2017; 29: 467–472.
Unlu O, Erkan D, Barbhaiya M, et al. The impact of systemic lupus erythematosus on the clinical phenotype of antiphospholipid antibody positive patients: results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository. Arthritis Care Res (Hoboken). 2019; 71: 134–141.
Carmi O, Berla M, Shoenfeld Y, et al. Diagnosis and management of catastrophic antiphospholipid syndrome. Expert Rev Hematol. 2017; 10: 365–374.
Fava A, Petri M. Systemic lupus erythematosus: diagnosis and clinical management. J Autoimmun. 2019; 96: 1–13.
Chasset F, Richez C, Martin T, et al. Rare diseases that mimic systemic lupus erythematosus (lupus mimickers). Joint Bone Spine. 2019; 86: 165–171.
Tamirou F, Husson SN, Gruson D, et al. Brief report: the Euro-Lupus low-dose intravenous cyclo¬phosphamide regimen does not impact the ovarian reserve, as measured by serum levels of anti¬Mullerian hormone. Arthritis Rheumatol. 2017; 69: 1267–1271.
Touma Z, Gladman DD. Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments. Lupus Sci Med. 2017; 4: 1–11.
Goswami RP, Sircar G, Sit H, et al. Cyclophosphamide versus mycophenolate versus rituximab in lupus nephritis remission induction: a historical head-to-head comparative study. J Clin Rheumatol. 2019; 25: 28–35.
Lai ZW, Kelly R, Winans T, et al. Sirolimus in patients with clinically active systemic lupus erythe¬matosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial. Lancet. 2018; 391: 1186–1196.
Barnes H, Holland AE, Westall GP, et al. Cyclophosphamide for connective tissue disease-associated interstitial lung disease. Cochrane Database Syst Rev. 2018; 1: CD010908.
Sircar G, Goswami RP, Sircar D, et al. Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. Rheumatology (Oxford). 2018; 57: 2106–2113.
Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016; 4: 708–719.
van Laar JM, Farge D, Sont JK, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA. 2014; 311: 2490–2498.
Sullivan KM, Goldmuntz EA, Keyes-Elstein L, et al. SCOT study investigators. Myeloablative autologous stem-cell transplantation in severe scleroderma. N Engl J Med. 2018; 378: 35–47.
Matucci-Cerinic M, Denton CP, Furst DE, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2011; 70: 32–38.
Hachulla E, Hatron PY, Carpentier P, et al. Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study. Ann Rheum Dis. 2016; 75: 1009–1015.
Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017; 390: 1685–1699.
Tratenberg M, Gutwein F, Rao V et al. Localized scleroderma: a clinical review. Curr Rheumatol Rev. 2017; 13: 86–92.
Mostmans Y, Cutolo M, Giddelo C, et al. The role of endothelial cells in the vasculopathy of systemic sclerosis: a systematic review. Autoimmun Rev. 2017; 16: 774–786.
Launay D, Sobanski V, Hachulla E, et al. Pulmonary hypertension in systemic sclerosis: different phenotypes. Eur Respir Rev. 2017; 26: 1–6.
Sakkas LI, Simopoulou T, Daoussis D, et al. Intestinal involvement in systemic sclerosis: a clinical review. Dig Dis Sci. 2018; 63: 834–844.
Denazas K, Ladas SD, Karamanolis GP. Evaluation and management of esophageal manifestations in systemic sclerosis. Ann Gastroenterol. 2018; 31: 165–170.
Rangarajan V Matiasz R, Freed BH. Cardiac complications of systemic sclerosis and management: recent progress. Curr Opin Rheumatol. 2017; 29: 574–584.
Zanatta E, Polito P, Favaro M, et al. Therapy of scleroderma renal crisis: state of the art. Autoimmun Rev. 2018; 17: 882–889.
Cutolo M, Smith V Furst DE, et al. Points to consider — Raynaud’s phenomenon in systemic sclerosis. Rheumatology (Oxford). 2017; 56 (suppl 5): v45–v48.
Brown M, O’Reilly S. The immunopathogenesis of fibrosis in systemic sclerosis. Clin Exp Immunol. 2019; 195: 310–321.
Knobler R, Moinzadeh P, Hunzelmann N, et al. European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes. J Eur Acad Dermatol Venereol. 2017; 31: 1401–1424.
Ferreli C, Gasparini G, Parodi A, et al. Cutaneous manifestations of scleroderma and scleroderma-like disorders: a comprehensive review. Clin Rev Allergy Immunol. 2017; 53: 306–336.
Belch J, Carlizza A, Carpentier PH, et al. ESVM guidelines—the diagnosis and management of Raynaud’s phenomenon. VASA. 2017; 46: 413–423.
Das A, Kumar A, Arrossi AV et al. Scleroderma-related interstitial lung disease: principles of management. Expert Rev Respir Med. 2019; 13: 357–367.
Woodworth TG, Suliman YA, Li W, et al. Scleroderma renal crisis and renal involvement in systemic sclerosis. Nat Rev Nephrol. 2016; 12: 678–691.
Smolenska Z, Barraclough R, Dorniak K, et al. Cardiac involvement in systemic sclerosis: diagnostic tools and evaluation methods. Cardiol Rev. 2019; 27: 73–79.
Dolcino M, Pelosi A, Fiore FF, et al. Gene profiling in patients with systemic sclerosis reveals the presence of oncogenic gene signatures. Front Immunol. 2018; 9: 1–20.
Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017; 76: 1327–1339.
Herrick AL, Pan X, Peytrignet S, et al. Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Ann Rheum Dis. 2017; 76: 1207–1218.
Poudel DR, Jayakumar D, Danve A, et al. Determinants of mortality in systemic sclerosis: a focused review. Rheumatol Int. 2018; 38: 1847–1858.
Hamad A, Lodi G, Porter S, et al. Interventions for dry mouth and hyposalivation in Sjogren’s syndrome: a systematic review and meta-analysis. Oral Dis. 2019; 25: 1027–1047.
Shih KC, Lun CN, Jhanji V et al. Systematic review of randomized controlled trials in the treatment of dry eye disease in Sjogren syndrome. J Inflamm (Lond). 2017; 14: 1–11.
Aragona P, Spinella R, Rania L, et al. Safety and efficacy of 0.1% clobetasone butyrate eyedrops in the treatment of dry eye in Sjogren syndrome. Eur J Ophthalmol. 2013; 23: 368–376.
Wang SQ Zhang LW, Wei P, et al. Is hydroxychloroquine effective in treating primary Sjogren’s syndrome? A systematic review and meta-analysis. BMC Musculoskelet Disord. 2017; 18: 1–13.
Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjogren’s syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010; 62: 960–968.
Devauchelle-Pensec V Mariette X, Jousse-Joulin S, et al. Treatment of primary Sjogren syndrome with rituximab: a randomized trial. Ann Intern Med. 2014; 160: 233–242.
Bowman SJ, Everett CC, O’Dwyer JL, et al. Randomized controlled trial of rituximab and cost- effectiveness analysis in treating fatigue and oral dryness in primary Sjogren’s syndrome. Arthritis Rheumatol. 2017; 69: 1440–1450.
Letaief H, Lukas C, Barnetche T, et al. Efficacy and safety of biological DMARDs modulating B cells in primary Sjogren’s syndrome: systematic review and meta-analysis. Joint Bone Spine. 2018; 85: 15–22.
Alani H, Henty JR, Thompson NL, et al. Systematic review and meta-analysis of the epidemiology ofpolyautoimmunity in Sjogren’s syndrome (secondary Sjogren’s syndrome) focusing on autoimmune rheumatic diseases. Scand J Rheumatol. 2018; 47: 141–154.
Rischmueller M, Tieu J, Lester S. Primary Sjogren’s syndrome. Best Pract Res Clin Rheumatol. 2016; 30: 189–220.
Qrn B, Wang J, Yang Z, et al. Epidemiology of primary Sjogren’s syndrome: a systematic review and meta-analysis. Ann Rheum Dis. 2015; 74: 1983–1989.
Maciel G, Crowson CS, Matteson EL, et al. Prevalence of primary Sjogren’s syndrome in a US population-based cohort. Arthritis Care Res (Hoboken). 2017; 69: 1612–1616.
Teos LY, Alevizos I. Genetics of Sjogren’s syndrome. Clin Immunol. 2017; 182: 41–47.
Nocturne G, Mariette X. B cells in the pathogenesis of primary Sjogren syndrome. Nat Rev Rheumatol. 2018; 14: 133–145.
Bhattarai KR, Junjappa R, Handigund M, et al. The imprint of salivary secretion in autoimmune disorders and related pathological conditions. Autoimmun Rev. 2018; 17: 376–390.
Alunno A, Leone MC, Giacomelli R, et al. Lymphoma and lymphomagenesis in primary Sjogren’s syndrome. Front Med (Lausanne). 2018; 5: 1–7.
Vasaitis L, Nordmark G, Theander E, et al. Comparison of patients with and without pre-existing lymphoma at diagnosis of primary Sjogren’s syndrome. Scand J Rheumatol. 2018; 1–6.
Tong L, Koh V Thong BY. Review of autoantigens in Sjogren’s syndrome: an update. J Inflamm Res. 2017; 10: 97–105.
Mirouse A, Seror R, Vicaut E, et al. Arthritis in primary Sjogren’s syndrome: characteristics, outcome and treatment from French multicenter retrospective study. Autoimmun Rev. 2019; 18: 9–14.
Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of Rheumatology / European League Against Rheumatism classification criteria for primary Sjogren’s syndrome: a consensus and data- driven methodology involving three international patient cohorts. Ann Rheum Dis. 2017; 76: 9–16.
Martire MV, Santiago ML, Cazenave T, et al. Latest advances in ultrasound assessment of salivary glands in Sjogren syndrome. J Clin Rheumatol. 2018; 24: 218–223.
Romao VC, Talarico R, Scire CA, et al. Sjogren’s syndrome: state of the art on clinical practice guidelines. RMD Open. 2018; 4: 1–8.
Andreu Sanchez JL, Fernandez Castro M, Del Campo Fontecha PD, et al. SER recommendations on the use of biological drugs in primary Sjogren’s syndrome. Reumatol Clin. 2019. [Epub ahead of print.]
Del Papa N, Vitali C. Management of primary Sjogren’s syndrome: recent developments and new classification criteria. Ther Adv Musculoskelet Dis. 2018; 10: 39–54.
Gordon PA, Winer JB, Hoogendijk JE, et al. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev. 2012; 8: CD003643.
Vermaak E, Tansley SL, McHugh NJ. The evidence for immunotherapy in dermatomyositis and polymyositis: a systematic review. Clin Rheumatol. 2015; 34: 2809–2095.
Oddis CV Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013; 65: 314–324.
Malik A, Hayat G, Kalia JS, et al. Idiopathic inflammatory myopathies: clinical approach and management. Front Neurol. 2016; 7: 1–19.
McHugh NJ, Tansley SL. Autoantibodies in myositis. Nat Rev Rheumatol. 2018; 14: 290–302.
Lundberg IE, Tjarnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their subgroups. Ann Rheum Dis. 2017; 76: 1955–1964.
Lundberg IE, de Visser M, Werth VP. Classification of myositis. Nat Rev Rheumatol. 2018; 14: 269–278.
Leclair V Lundberg IE. New myositis classification criteria—what we have learned since Bohan and Peter. Curr Rheumatol Rep. 2018; 20: 1–8.
Jabari D, Vedanarayanan VV Barohn RJ, et al. Update on inclusion body myositis. Curr Rheumatol Rep. 2018; 20: 1–8.
Meyer A, Meyer N, Schaeffer M, et al. Incidence and prevalence of inflammatory myopathies: a systematic review. Rheumatology (Oxford). 2015; 54: 50–63.
Palterer B, Vitiello G, Carraresi A, et al. Bench to bedside review of myositis autoantibodies. Clin Mol Allergy. 2018; 16: 1–17.
Pinal-Fernandez I, Casal-Dominguez M, Mammen AL. Immune-mediated necrotizing myopathy. Curr Rheumatol Rep. 2018; 20: 1–10.
Allenbach Y Mammen AL, Benveniste O, Immune-Mediated Necrotizing Myopathies Working Group, et al. 224th ENMC International Workshop: clinico-sero-pathological classification of immune-mediated necrotizing myopathies. Zandvoort, The Netherlands, 14-October 16, 2016. Neuromuscul Disord. 2018; 28: 87–99.
Herbelet S, De Bleecker JL. Immune checkpoint failures in inflammatory myopathies: an overview. Autoimmun Rev. 2018; 17: 746–754.
Britson KA, Yang SY, Lloyd TE. New developments in the genetics of inclusion body myositis. Curr Rheumatol Rep. 2018; 20: 1–8.
Jones J, Wortmann R. Idiopathic inflammatory myopathies-a review. Clin Rheumatol. 2015; 34: 839–844.
Mainetti C, Terziroli Beretta-Piccoli B, Selmi C. Cutaneous manifestations of dermatomyositis: a comprehensive review. Clin Rev Allergy Immunol. 2017; 53: 337–356.
Concha JSS, Patsatsi A, Marshak-Rothstein A, et al. Advances in cutaneous lupus erythematosus and dermatomyositis: a report from the 4th International Conference on Cutaneous Lupus Erythematosus—an ongoing need for international consensus and collaborations. J Invest Dermatol. 2019; 139: 270–276.
Lepreux S, Hainfellner JA, Vital A. Idiopathic inflammatory myopathies overlapping with systemic diseases. Clin Neuropathol 2018; 37: 6–15.
Greenberg SA. Inclusion body myositis: clinical features and pathogenesis. Nat Rev Rheumatol. 2019. [Epub ahead of print.]
Perez-Baos S, Prieto-Potin I, Roman-Blas JA, et al. Mediators and patterns of muscle loss in chronic systemic inflammation. Front Physiol. 2018; 9: 1–14.
de Souza FHC, de Araujo DB, Vilela VS, et al. Guidelines of the Brazilian Society of Rheumatology for the treatment of systemic autoimmune myopathies. Adv Rheumatol. 2019; 59: 6.
Kohsaka H, Mimori T, Kanda T, et al. Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists. J Dermatol. 2019; 46: e1–e18.
Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017; 377: 317–328.
Nakaoka Y, Isobe M, Takei S, et al. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis. 2018; 77: 348–354.
Hamada H, Suzuki H, Onouchi Y, et al. Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial. Lancet. 2019; 393: 1128–1137.
Wardle AJ, Connolly GM, Seager MJ, et al. Corticosteroids for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev. 2017; 1: CD011188.
Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for remission induction in ANCA-associated vasculitis. N Engl J Med. 2010; 363: 221–232.
Specks U, Merkel PA, Seo P, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med. 2013; 369: 417–427.
Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA- associated vasculitis. N Engl J Med. 2014; 371: 1771–1780.
Wechsler ME, Akuthota P, Jayne D, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2017; 376: 1921–1932.
Hatemi G, Melikoglu M, Tunc R, et al. Apremilast for Behcet’s syndrome — a phase 2, placebo- controlled study. N Engl J Med. 2015; 372: 1510–1518.
Kim ESH, Beckman J. Takayasu arteritis: challenges in diagnosis and management. Heart. 2018; 104: 558–565.
Barra L, Yang G, Pagnoux C, et al. Non-glucocorticoid drugs for the treatment of Takayasu’s arteritis: a systematic review and meta-analysis. Autoimmun Rev. 2018; 17: 683–693.
Comarmond C, Biard L, Lambert M, et al. Long-term outcomes and prognostic factors of complications in Takayasu arteritis: a multicenter study of 318 patients. Circulation. 2017; 136: 1114–1122.
van der Geest KSM, Sandovici M, van Sleen Y, et al. What is the current evidence for disease subsets in giant cell arteritis? Arthritis Rheumatol. 2018; 70: 1366–1376.
Forbess L, Bannykh S. Polyarteritis nodosa. Rheum Dis Clin North Am. 2015; 41: 33–46.
Karadag O, Jayne DJ. Polyarteritis nodosa revisited: a review of historical approaches, subphenotypes and a research agenda. Clin Exp Rheumatol. 2018; 36 Suppl 111: 135–142.
Sosa T, Brower L, Divanovic A. Diagnosis and management of Kawasaki disease. JAMA Pediatr. 2019. [Epub ahead of print.]
Liu YC, Lin MT, Wang JK, et al. State-of-the-art acute phase management of Kawasaki disease after 2017 scientific statement from the American Heart Association. Pediatr Neonatol 2018; 59: 543–552.
Lamprecht P, Kerstein A, Klapa S, et al. Pathogenetic and clinical aspects of anti-neutrophil cytoplasmic autoantibody-associated vasculitides. Front Immunol. 2018; 9: 1–10.
Lynch JP 3rd, Derhovanessian A, Tazelaar H, et al. Granulomatosis with polyangiitis (Wegener’s granulomatosis): evolving concepts in treatment. Semin Respir Crit Care Med. 2018; 39: 434–458.
Cornec D, Kabat BF, Mills JR, et al. Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis. Rheumatology (Oxford). 2018; 57: 639–650.
Wallace ZS, Wallwork R, Zhang Y, et al. Improved survival with renal transplantation for end-stage renal disease due to granulomatosis with polyangiitis: data from the United States Renal Data System. Ann Rheum Dis. 2018; 77: 1333–1338.
Raffray L, Guillevin L. Treatment of eosinophilic granulomatosis with polyangiitis: a review. Drugs. 2018; 78: 809–821.
Kolopp-Sarda MN, Miossec P. Cryoglobulins: an update on detection, mechanisms and clinical contribution. Autoimmun Rev. 2018; 17: 457–464.
Roccatello D, Sciascia S, Rossi D, et al. The challenge of treating hepatitis C virus-associated cryoglobulinemic vasculitis in the era of anti-CD20 monoclonal antibodies and direct antiviral agents. Oncotarget. 2017; 8: 41764–41777.
Durtette C, Hachulla E, Resche-Rigon M, et al. Cogan syndrome: characteristics, outcome and treatment in a French nationwide retrospective study and literature review. Autoimmun Rev. 2017; 16: 1219–1223.
Greco A, De Virgilio A, Ralli M, et al. Behcet’s disease: new insights into pathophysiology, clinical features and treatment options. Autoimmun Rev. 2018; 17: 567–575.
Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behcet’s syndrome. Ann Rheum Dis. 2018; 77: 808–818.
Byram K, Hajj-Ali RA, Calabrese L. CNS vasculitis: an approach to differential diagnosis and management. Curr Rheumatol Rep. 2018; 20: 1–7.
Cappelen-Smith C, Calic Z, Cordato D. Reversible cerebral vasoconstriction syndrome: recognition and treatment. Curr Treat Options Neurol. 2017; 19: 1–1.
Villiger PM, Adler S, Kuchen S, et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2016; 387: 1921–1927.
Stone J, et al. Tocilizumab for sustained glucocorticoid-free remission in giant cell arteritis. N Engl JMed. 2017; 377: 317–328.
Yates M, Loke YK, Watts RA, et al. Prednisolone combined with adjunctive immunosuppression is not superior to prednisolone alone in terms of efficacy and safety in giant cell arteritis: meta-analysis. Clin Rheumatol. 2014; 33: 227–236.
Langford CA, et al. A randomized double-blind trial of abatacept and glucocorticoids for the treatment of giant cell arteritis. Arthritis Rheumatol. 2015; 67: 3949–3951.
Gonzalez-Gay MA, Mattesor EL, Castaneda S. Polymyalgia rheumatic. Lancet. 2017; 390: 1700–1712.
Dejaco C, Brouwer E, Mason JC, et al. Giant cell arteritis and polymyaligia rheumatic. Nat Rev Rheumatol. 2017; 13: 578–592.
Gilden D, White T, Boyer PJ, et al. Varicella zoster virus infection in granulomatous arteritis of the aorta. J Infect Dis. 2016; 213: 1866–1871.
Rinagel M, Chatelus E, Jousse-Joulin S, et al. Diagnostic performance of temporal artery ultrasound for the diagnosis of giant cell arteritis: a systematic review and meta-analysis of the literature. Autoim- mun Rev. 2019; 18: 56–61.
Prieto-Gonzalez S, Villarreal-Compagny M, Cid MC. Imaging in the management of giant cell arteritis. Med Clin (Barc). 2019. [Epub ahead of print.]
Baig IF, Pascoe AR, Kini A, et al. Giant cell arteritis: early diagnosis is key. Eye Brain. 2019; 11: 1–12.
Keser G, Aksu K. Diagnosis and differential diagnosis of large-vessel vasculitides. Rheumatol Int. 2019; 39: 169–185.
Dejaco C, Singh YP, Perel P, et al. 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2015; 74: 1799–1807.
Buttgereit F, Dejaco C, Matteson EL, et al. Polymyalgia rheumatica and giant cell arteritis: a systematic review. JAMA. 2016; 315: 2442–2458.
Strand V, Dimonaco S, Tuckwell K, et al. Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial. Arthritis Res Ther. 2019; 21: 1–9.
Lally L, Forbess L, Hatzis C, et al. Efficacy and safety of tocilizumab for the treatment of polymyalgia rheumatic. Arthritis Rheumatol. 2016; 68: 2550–2554.
Devauchelle-Pensec V, et al. Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study. Ann Rheum Dis. 2016; 75: 1506–1510.
Li L, Neogi T, Jick S. Giant cell arteritis and vascular disease-risk factors and outcomes: a cohort study using UK Clinical Practice Research Datalink. Rheumatology (Oxford). 2017; 56: 753–762.
Qin YF, Li ZJ, Li H. Corticosteroids as adjunctive therapy with antibiotics in the treatment of children with septic arthritis: a meta-analysis. Drug Des Devel Ther. 2018; 12: 2277–2284.
Li HK, Rombach I, Zambellas R, et al. Oral versus intravenous antibiotics for bone and joint infection. N Engl J Med. 2019; 380: 425–436.
Rappo U, Puttagunta S, Shevchenko V, et al. Dalbavancin for the treatment of osteomyelitis in adult patients: a randomized clinical trial of efficacy and safety. Open Forum Infect Dis. 2019; 6: 1–8.
Bernard L, Dinh A, Ghout I, et al. Antibiotic treatment for 6 weeks versus 12 weeks in patients with pyogenic vertebral osteomyelitis: an open-label, non-inferiority, randomised, controlled trial. Lancet. 2015; 385: 875–882.
Lieber SB, Fowler ML, Zhu C, et al. Clinical characteristics and outcomes of septic bursitis. Infection. 2017; 45: 781–786.
Ross JJ. Septic arthritis of native joints. Infect Dis Clin North Am. 2017; 31: 203–218.
Costales C, Butler-Wu SM. A real pain: diagnostic quandaries and septic arthritis. J Clin Microbiol. 2018; 56: 1–10.
Simpfendorfer CS. Radiologic approach to musculoskeletal infections. Infect Dis Clin North Am. 2017; 31: 299–324.
Hassan AS, Rao A, Manadan AM, et al. Peripheral bacterial septic arthritis: review of diagnosis and management. J Clin Rheumatol. 2017; 23: 435–442.
Flores-Robles BJ, Jimenez Palop M, Sanabria Sanchinel AA, et al. Medical versus surgical approach to initial treatment in septic arthritis: a single Spanish center’s 8-year experience. J Clin Rheumatol. 2019; 25: 4–8.
Runowska M, Majewski D, Niklas K, et al. Chikungunya virus: a rheumatologist’s perspective. Clin Exp Rheumatol. 2018; 36: 494–501.
Moizeis RNC, Fernandes T, Guedes P, et al. Chikungunya fever: a threat to global public health. Pathog Glob Health. 2018; 112: 182–194.
Sutaria RB, Amaral JK, Schoen RT. Emergence and treatment of chikungunya arthritis. Curr Opin Rheumatol. 2018; 30: 256–263.
Henry MW, Miller AO, Walsh TJ, et al. Fungal musculoskeletal infections. Infect Dis Clin North Am. 2017; 31: 353–368.
Hogan JI, Hurtado RM, Nelson SB. Mycobacterial musculoskeletal infections. Infect Dis Clin North Am. 2017; 31: 369–382.
Nair R, Schweizer ML, Singh N. Septic arthritis and prosthetic joint infections in older adults. Infect Dis Clin North Am. 2017; 31: 715–729.
Ting NT, Della Valle CJ. Diagnosis of periprosthetic joint infection — an algorithm-based approach. J Arthroplasty. 2017; 32: 2047–2050.
Tande AJ, Gomez-Urena EO, Berbari EF, et al. Management of prosthetic joint infection. Infect Dis Clin North Am. 2017; 31: 237–252.
Berrios-Torres SI, Umscheid CA, Bratzler DW, et al. Centers for Disease Control and Prevention guideline for the prevention of surgical site infection, 2017. JAMA Surg. 2017; 152: 784–791.
Parvizi J, Shohat N, Gehrke T. Prevention of periprosthetic joint infection: new guidelines. Bone Joint J. 2017; 99-b: 3–10.
Goodman SM, Springer B, Guyatt G, et al. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty. Arthritis Rheumatol. 2017; 69: 1538–1551.
Giurato L, Meloni M, Izzo V, et al. Osteomyelitis in diabetic foot: a comprehensive overview. World J Diabetes. 2017; 8: 135–142.
Kavanagh N, Ryan EJ, Widaa A, et al. Staphylococcal osteomyelitis: disease progression, treatment challenges, and future directions. Clin Microbiol Rev. 2018; 31: 1–25.
Lam K, van Asten SA, Nguyen T, et al. Diagnostic accuracy of probe to bone to detect osteomyelitis in the diabetic foot: a systematic review. Clin Infect Dis. 2016; 63: 944–948.
Thabit AK, Fatani DF, Bamakhrama MS, et al. Antibiotic penetration into bone and joints: an updated review. Int J Infect Dis. 2019; 81: 128–136.
Senneville E, Robineau O. Treatment options for diabetic foot osteomyelitis. Expert Opin Pharma- cother. 2017; 18: 759–765.
Berbari EF, Kanj SS, Kowalski TJ, et al. Executive summary: 2015 Infectious Diseases Society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. Clin Infect Dis. 2015; 61: 859–863.
Dunn RN, Ben Husien M. Spinal tuberculosis. Bone Joint J. 2018; 100-b: 425–431.
Nielsen SM, Bartels EM, Henriksen M, et al. Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies. Ann Rheum Dis. 2017; 76: 1870–1882.
van Durme CM, Wechalekar MD, Buchbinder R, et al. Non-steroidal anti-inflammatory drugs for acute gout. Cochrane Database Syst Rev. 2014; 9: CD010120.
van Echteld I, Wechalekar MD, Schlesinger N, et al. Colchicine for acute gout. Cochrane Database Syst Rev. 2014; 8: CD006190.
Yu J, Lu H, Zhou J, et al. Oral prednisolone versus non-steroidal anti-inflammatory drugs in the treatment of acute gout: a meta-analysis of randomized controlled trials. Inflammopharmacology. 2018; 26: 717–723.
Seth R, Kydd AS, Buchbinder R, et al. Allopurinol for chronic gout. Cochrane Database Syst Rev. 2014; 10: CD006077.
Stamp LK, Chapman PT, Barclay ML, et al. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Ann Rheum Dis. 2017; 76: 1522–1528.
White WB, Saag KG, Becker MA, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018; 378: 1200–1210.
Kydd AS, Seth R, Buchbinder R, et al. Uricosuric medications for chronic gout. Cochrane Database Syst Rev. 2014; 11: CD010457.
Perez-Ruiz F, Sundy JS, Miner JN, et al. Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol. Ann Rheum Dis. 2016; 75: 1074–1080.
Hill EM, Sky K, Sit M, et al. Does starting allopurinol prolong acute treated gout? A randomized clinical trial. J Clin Rheumatol. 2015; 21: 120–125.
Kuo CF, Grainge MJ, Zhang W, et al. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015; 11: 649–662.
Major TJ, Dalbeth N, Stahl EA, et al. An update on the genetics of hyperuricaemia and gout. Nat Rev Rheumatol. 2018; 14: 341–353.
Desai J, Steiger S, Anders HJ. Molecular pathophysiology of gout. Trends Mol Med. 2017; 23: 756–768.
So AK, Martinon F. Inflammation in gout: mechanisms and therapeutic targets. Nat Rev Rheumatol. 2017; 13: 639–647.
Neogi T, Jansen TL, Dalbeth N, et al. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2015; 74: 1789–1798.
Taylor WJ, Fransen J, Jansen TL, et al. Study for updated gout classification criteria: identification of features to classify gout. Arthritis Care Res (Hoboken). 2015; 67: 1304–1315.
Burns RB, Smith CC, Shmerling RH, et al. How would you manage this patient with gout? Grand rounds discussion from Beth Israel Deaconess Medical Center. Ann Intern Med. 2018; 169: 788–795.
Singh JA. Patient perspectives in gout: a review. Curr Opin Rheumatol. 2019; 31: 159–166.
Bardin T, Richette P. The role of febuxostat in gout. Curr Opin Rheumatol. 2019; 31: 152–158.
Sidari A, Hill E. Diagnosis and treatment of gout and pseudogout for everyday practice. Prim Care. 2018; 45: 213–236.
Rosenthal AK, Ryan LM. Calcium pyrophosphate deposition disease. N Engl J Med. 2016; 374: 2575–2584.
Loffler C, Sattler H, Peters L, et al. Distinguishing gouty arthritis from calcium pyrophosphate disease and other arthritides. J Rheumatol. 2015; 42: 513–520.
Andr?s M, Sivera F, Pascual E. Therapy for CPPD: options and evidence. Curr Rheumatol Rep. 2018; 20: 1–6.
Frallonardo P, Ramonda R, Peruzzo L, et al. Basic calcium phosphate and pyrophosphate crystals in early and late osteoarthritis: relationship with clinical indices and inflammation. Clin Rheumatol. 2018; 37: 2847–2853.
Jost J, Bahans C, Courbebaisse M, et al. Topical sodium thiosulfate: a treatment for calcifications in hyperphosphatemic familial tumoral calcinosis? J Clin Endocrinol Metab. 2016; 101: 2810–2815.
Macfarlane GJ, Kronisch C, Atzeni F, et al. EULAR recommendations for management of fibromyalgia. Ann Rheum Dis. 2017; 76: 318–328.
Moore RA, Derry S, Aldington D, et al. Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2012; 12: CD008242.
Moldofsky H, Harris HW, Archambault WT, et al. Effects of bedtime very low dose cyclobenzaprine on symptoms and sleep physiology in patients with fibromyalgia syndrome: a double-blind randomized placebo-controlled study. J Rheumatol. 2011; 38: 2653–2663.
Welsch P, Bernardy K, Derry S, et al. Mirtazapine for fibromyalgia in adults. Cochrane Database Syst Rev. 2018; 8: CD012708.
Welsch P, Uceyler N, Klose P, et al. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia. Cochrane Database Syst Rev. 2018; 2: CD010292.
Arnold LM, Hirsch I, Sanders P, et al. Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen-week, randomized, double-blind, placebo-controlled, multicenter clinical trial. Arthritis Rheum. 2012; 64: 2387–2397.
Derry S, Cording M, Wiffen PJ, et al. Pregabalin for pain in fibromyalgia in adults. Cochrane Database Syst Rev. 2016; 9: CD011790.
Olivan-Blazquez B, Herrera-Mercadal P, Puebla-Guedea M, et al. Efficacy of memantine in the treatment of fibromyalgia: a double-blind, randomised, controlled trial with 6-month follow-up. Pain. 2014; 155: 2517–2525.
Walitt B, Klose P, Fitzcharles MA, et al. Cannabinoids for fibromyalgia. Cochrane Database Syst Rev. 2016; 7: CD011694.
Derry S, Wiffen PJ, Hauser W, et al. Oral nonsteroidal anti-inflammatory drugs for fibromyalgia in adults. Cochrane Database Syst Rev. 2017; 3: CD012332.
Pridgen WL, Duffy C, Gendreau JF, et al. A famciclovir + celecoxib combination treatment is safe and efficacious in the treatment of fibromyalgia. J Pain Res. 2017; 10: 451–460.
Gilron I, Chaparro LE, Tu D, et al. Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial. Pain. 2016; 157: 1532–1540.
Bidonde J, Busch AJ, Schachter CL, et al. Aerobic exercise training for adults with fibromyalgia. Cochrane Database Syst Rev. 2017; 6: CD012700.
Lumley MA, Schubiner H, Lockhart NA, et al. Emotional awareness and expression therapy, cognitive behavioral therapy, and education for fibromyalgia: a cluster-randomized controlled trial. Pain. 2017; 158: 2354–2363.
Natelson BH. Myalgic encephalomyelitis/chronic fatigue syndrome and fibromyalgia: definitions, similarities, and differences. Clin Ther. 2019. [Epub ahead of print.]
Martini A, Schweiger V, Del Balzo G, et al. Epidemiological, pharmacological and sociodemographic characterisation of a population of 386 fibromyalgic patients referred to a tertiary pain centre in Italy. Clin Exp Rheumatol. 2019; 37 (suppl 116): 27–38.
Brummett CM, Urquhart AG, Hassett AL, et al. Characteristics of fibromyalgia independently predict poorer long-term analgesic outcomes following total knee and hip arthroplasty. Arthritis Rheumatol. 2015; 67: 1386–1394.
Sluka KA, Clauw DJ. Neurobiology of fibromyalgia and chronic widespread pain. Neuroscience. 2016; 338: 114–129.
Ciampi de Andrade D, Maschietto M, Galhardoni R, et al. Epigenetics insights into chronic pain: DNA hypomethylation in fibromyalgia—a controlled pilot-study. Pain. 2017; 158: 1473–1480.
Lopez-Sola M, Woo CW, Pujol J, et al. Towards a neurophysiological signature for fibromyalgia. Pain. 2017; 158: 34–47.
Wolfe F, Clauw DJ, Fitzcharles MA, et al. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum. 2016; 46: 319–329.
Garda-Rfos MC, Navarro-Ledesma S, Tapia-Haro RM, et al. Effectiveness of health education in patients with fibromyalgia: a systematic review. Eur JPhys RehabilMed. 2019. [Epub ahead of print.]
Arnold LM, Clauw DJ. Challenges of implementing fibromyalgia treatment guidelines in current clinical practice. Postgrad Med. 2017; 129: 709-714.
Selmi C, Generali E, Gershwin ME. Rheumatic manifestations in autoimmune liver disease. Rheum Dis Clin North Am. 2018; 44: 65–87.
Gronbaek L, Vilstrup H, Pedersen L, et al. Extrahepatic autoimmune diseases in patients with autoimmune hepatitis and their relatives: a Danish nationwide cohort study. Liver Int. 2019; 39: 205–214.
Puechal X. Whipple’s arthritis. Joint Bone Spine. 2016; 83: 631–635.
Marth T, Moos V Muller C, et al. Tropheryma whipplei infection and Whipple’s disease. Lancet Infect Dis. 2016; 16: e13–e22.
Isasi C, Tejerina E, Moran LM. Non-celiac gluten sensitivity and rheumatic diseases. Reumatol Clin. 2016; 12: 4–10.
Kang DJ, Lee SJ, Choo HJ, et al. Pancreatitis, panniculitis, and polyarthritis (PPP) syndrome: MRI features of intraosseous fat necrosis involving the feet and knees. Skeletal Radiol. 2017; 46: 279–285.
Hughes M, Akram Q, Rees DC, et al. Haemoglobinopathies and the rheumatologist. Rheumatology (Oxford). 2016; 55: 2109–2118.
Dimitriades VR, Sorensen R. Rheumatologic manifestations of primary immunodeficiency diseases. Clin Rheumatol. 2016; 35: 843–850.
Nguyen TX, Naqvi A, Thompson TL, et al. Musculoskeletal manifestations of amyloidosis: a focused review. J Surg Orthop Adv. 2018; 27: 1–5.
Dong Q, Liu H, Yang D, et al. Diabetes mellitus and arthritis: is it a risk factor or comorbidity? A systematic review and meta-analysis. Medicine (Baltimore). 2017; 96: 1–6.
Sozen T, Basaran NQ Tinazli M, et al. Musculoskeletal problems in diabetes mellitus. EurJ Rheumatol. 2018; 5: 258–265.
Francia P, Anichini R, Seghieri G, et al. History, prevalence and assessment of limited joint mobility, from stiff hand syndrome to diabetic foot ulcer prevention: a narrative review of the literature. Curr Diabetes Rev. 2018; 14: 411–426.
Mella JR, Guo L, Hung V. Dupuytren’s contracture: an evidence based review. Ann Plast Surg. 2018; 81: S97–S101.
Toz B, Buyukbabani N, Inanc M. Multicentric reticulohistiocytosis: rheumatology perspective. Best Pract Res Clin Rheumatol. 2016; 30: 250–260.
Kobak S, Sever F, Usluer O, et al. The clinical characteristics of sarcoid arthropathy based on a prospective cohort study. Ther Adv Musculoskelet Dis. 2016; 8: 220–224.
Haldar D, Cockwell P, Richter AG, et al. An overview of the diagnosis and management of immunoglobulin G4-related disease. CMAJ. 2016; 188: 953–961.
Sebastian A, Sebastian M, Misterska-Skora M, et al. The variety of clinical presentations in IgG4-related disease in rheumatology. Rheumatol Int. 2018; 38: 303–309.
Taylor AM, Hsueh MF, Ranganath LR, et al. Cartilage biomarkers in the osteoarthropathy of alkaptonuria reveal low turnover and accelerated ageing. Rheumatology (Oxford). 2017; 56: 156–164.
Mathian A, Miyara M, Cohen-Aubart F, et al. Relapsing polychondritis: a 2016 update on clinical features, diagnostic tools, treatment and biological drug use. Best Pract Res Clin Rheumatol. 2016; 30: 316–333.
Gouin F, Noailles T. Localized and diffuse forms of tenosynovial giant cell tumor (formerly giant cell tumor of the tendon sheath and pigmented villonodular synovitis). Orthop Traumatol Surg Res. 2017; 103: S91–S97.
Sihvonen R, Paavola M, Malmivaara A, et al. Arthroscopic partial meniscectomy versus placebo surgery for a degenerative meniscus tear: a 2-year follow-up of the randomised controlled trial. Ann Rheum Dis. 2018; 77: 188–195.
van de Graaf VA, Wolterbeek N, Mutsaerts EL, et al. Arthroscopic partial meniscectomy or conservative treatment for nonobstructive meniscal tears: a systematic review and meta-analysis of randomized controlled trials. Arthroscopy. 2016; 32: 1855–1865.
Sihvonen R, Englund M, Turkiewicz A, et al. Mechanical symptoms and arthroscopic partial meniscectomy in patients with degenerative meniscus tear: a secondary analysis of a randomized trial. Ann Intern Med. 2016; 164: 449–455.
Abram SGF, Hopewell S, Monk AP, et al. Arthroscopic partial meniscectomy for meniscal tears of the knee: a systematic review and meta-analysis. Br J Sports Med. 2019. [Epub ahead of print.]
Beard DJ, Rees JL, Cook JA, et al. Arthroscopic subacromial decompression for subacromial shoulder pain (CSAW): a multicentre, pragmatic, parallel group, placebo-controlled, three-group, randomised surgical trial. Lancet. 2018; 391: 329–338.
Paavola M, Malmivaara A, Taimela S, et al. Subacromial decompression versus diagnostic arthroscopy for shoulder impingement: randomised, placebo surgery controlled clinical trial. BMJ. 2018; 362: 1–11.
Griffin DR, Dickenson EJ, Wall PDH, et al. Hip arthroscopy versus best conservative care for the treatment of femoroacetabular impingement syndrome (UK FASHIoN): a multicentre randomised controlled trial. Lancet. 2018; 391: 2225–2235.
Skou ST, Roos EM, Laursen MB. A randomized, controlled trial of total knee replacement. N Engl J Med. 2016; 373: 1597–1606.
Kurd MF, Kreitz T, Schroeder G, Vaccaro AR. The role of multimodal analgesia in spine surgery. J Am Acad Orthop Surg. 2017; 25: 260–268.
Codding JL, Getz CL. Pain management strategies in shoulder arthroplasty. Orthop Clin North Am. 2018; 49: 81–91.
Shim JW, Park MJ. Arthroscopic synovectomy of wrist in rheumatoid arthritis. Hand Clin. 2017; 33: 779–785.
Lawton CD, Butler BA, Dekker RG 2nd, et al. Total ankle arthroplasty versus ankle arthrodesis—a comparison of outcomes over the last decade. J Orthop Surg Res. 2017; 12: 1–10.
Ferguson RJ, Palmer AJ, Taylor A, et al. Hip replacement. Lancet. 2018; 392: 1662–1671.
Evans JT, Evans JP, Walker RW, et al. How long does a hip replacement last? A systematic review and meta-analysis of case series and national registry reports with more than 15 years of follow-up. Lancet. 2019; 393: 647–654.
Price AJ, Alvand A, Troelsen A, et al. Knee replacement. Lancet. 2018; 392: 1672–1682.
Kooistra BW, Willems WJ, Lemmens E, et al. Comparative study of total shoulder arthroplasty versus total shoulder surface replacement for glenohumeral osteoarthritis with minimum 2-year follow-up. J Shoulder Elbow Surg. 2017; 26: 430–436.
Hellman MD, Ford MC, Barrack RL. Is there evidence to support an indication for surface replacement arthroplasty? A systematic review. Bone Joint J. 2019; 101-b: 32–40.
Levin ES, Plotkin B. Elbow arthroplasty: from normal to failure. Semin Musculoskelet Radiol. 2019; 23: 141–150.
Godoy DA, Di Napoli M, Rabinstein AA. Cerebral fat embolism: recognition, complications, and prognosis. Neurocrit Care. 2018; 29: 358–365.
Goodman SM, Spinger B, Guyatt G, et al. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guidelines for the perioperative management of Anti-Rheumatic medication in patients with rheumatic diseases undergoing elective total hip and knee arthroplasty. Arthritis Rheumatol. 2017; 69: 1538–1551.
